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Innate sensing of microbial products promotes
wound-induced skin cancer
Esther Hoste1,2, Esther N. Arwert1, Rohit Lal3, Andrew P. South4,5, Julio C. Salas-Alanis6,
Dedee F. Murrell7, Giacomo Donati1,2 & Fiona M. Watt2
The association between tissue damage, chronic inflammation and cancer is well known.
However, the underlying mechanisms are unclear. Here we characterize a mouse model in
which constitutive epidermal extracellular-signal-regulated kinase-MAP-kinase signalling
results in epidermal inflammation, and skin wounding induces tumours. We show that tumour
incidence correlates with wound size and inflammatory infiltrate. Ablation of tumour necrosis
factor receptor (TNFR)-1/-2, Myeloid Differentiation primary response gene 88 or Toll-like
receptor (TLR)-5, the bacterial flagellin receptor, but not other innate immune sensors, in
radiosensitive leukocytes protects against tumour formation. Antibiotic treatment inhibits,
whereas injection of flagellin induces, tumours in a TLR-5-dependent manner. TLR-5 is also
involved in chemical-induced skin carcinogenesis in wild-type mice. Leukocytic TLR-5 sig-
nalling mediates upregulation of the alarmin HMGB1 (High Mobility Group Box 1) in wound-
induced papillomas. HMGB1 is elevated in tumours of patients with Recessive Dystrophic
Epidermolysis Bullosa, a disease characterized by chronic skin damage. We conclude that in
our experimental model the combination of bacteria, chronic inflammation and wounding
cooperate to trigger skin cancer.
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T
he association between skin wounding, inflammation and
cancer is well established1,2. For example, Marjolin’s ulcers
are aggressive squamous cell carcinomas (SCCs) that
specifically develop on areas of previous skin trauma3. Keloid
scarring is a consequence of aberrant wound healing and is also
described as benign fibrotic tumour formation4. In addition,
malignancies at wound sites are often overlooked in chronic
ulcers in diabetic and elderly patients5. Another context in which
the association between skin wounding and cancer is well
established is Recessive Dystrophic Epidermolysis Bullosa
(RDEB). This inherited skin blistering disease is characterized
by repetitive cycles of wounding and repair and is linked with a
high incidence of SCC formation. Almost 100% of RDEB patients
will develop at least one SCC6. However, despite the clear link
between skin damage and cancer, little is known about the
underlying mechanisms.
We previously described a mouse model of wound-induced
skin cancer that mimics key features of human hyperproliferative
skin conditions. Wounded human skin and psoriatic lesions are
characterized by misexpression of b1 integrin extracellular matrix
receptors in the differentiating epidermal cell layers, and
consequent upregulation of extracellular signal-regulated kinase-
MAP-kinase signalling7. When this is modelled in transgenic
mice by expression of constitutively active MAP-kinase kinase 1
under the control of the involucrin promoter (InvEE mice), there
is chronic skin inflammation and epidermal hyperproliferation,
and mice develop benign tumours (papillomas) on wounding8,9.
We previously identified a pro-tumorigenic role for macrophages
and peripheral gdT cells in this model8.
Here we set out to identify the molecular signalling events that
underlie the link between chronic inflammation, tissue damage
and skin cancer. We have found a previously unknown role for
Toll-like receptor (TLR)-5, the receptor for bacterial flagellin, in
skin tumour formation, both in the InvEE mouse model and in
wild-type (WT) mice treated with chemical carcinogens. We
further show that TLR-5 plays a role in upregulation of the
alarmin HMGB1 (High Mobility Group Box 1) in wound-
induced mouse tumours and demonstrate that HMGB1 is also
elevated in tumours of RDEB patients.
Results
Effect of wound size and immune infiltrate on tumorigenesis.
To test whether wound size, wound closure rate or inflammatory
response to wounding influenced tumour incidence, full-thick-
ness skin wounds of different sizes (2, 4, 5, 6 and 8mm2) were
made on back skin of WT and InvEE (Inv) mice, and papilloma
formation at the wound site was monitored. Wounds in InvEE
and WT littermates healed at the same rate but only InvEE mice
developed tumours (Supplementary Fig. 1a,b). Although onset of
tumour formation was independent of wound size, there was a
linear correlation between wound size and tumour incidence
(R2¼ 0.91381; Fig. 1a,b). Wound size and total immune cell
infiltrate (CD45þ cells) were correlated in both WT and InvEE
skin, but CD45þ cells were significantly more abundant in InvEE
skin both before wounding9 and at the time of wound closure
(Fig. 1c and Supplementary Fig. 1c,d). There were even more
CD45þ cells in the tumour stroma than in newly closed 8mm2
InvEE wounds (Fig. 1c). These results indicate that the degree of
inflammation remaining once the acute response to injury has
resolved correlates with the extent of the primary insult and
subsequent tumour incidence.
As nuclear factor-kB (NF-kB) is an important mediator of
inflammation-associated cancer10, we analysed expression
of NF-kB target genes in InvEE and control epidermis. All 16 of
the genes examined were significantly upregulated in InvEE
epidermis relative to WT epidermis (Po0.0001 for each
individual gene product; Fig. 1d). The effects were systemic, as
levels of thymic stromal lymphopoietin (TSLP), tumour-necrosis
factor (TNF)-a and interleukin (IL)-6 were elevated in serum of
tumour-free InvEE mice and increased further in tumour-bearing
animals (Fig. 1e–g).
Tumour formation requires haematopoietic TNFR signalling.
TNF-a is well known for its context-dependent pro- and
anti-tumorigenic roles11 and downstream TNF-a signalling is
mediated by TNFR-1 and TNFR-2. Mice deficient in both
receptors are resistant to skin cancer induced by chemical
carcinogens12. To examine whether wound-induced tumor-
igenesis was dependent on TNFR signalling specifically in
leukocytes, sub-lethally irradiated InvEE mice were
reconstituted with TNFR-1/-2 / (TNFR / ) bone marrow
(BM) and subsequently wounded. Successful engraftment
was verified by Y chromosome-fluorescence in situ
hybridization (Y-FISH) in spleens of reconstituted mice as
previously described8 (Supplementary Fig. 2a).
TNFR / chimeric mice were highly resistant to wound-
induced tumour formation (Fig. 2a). Only 8.3% of TNFR /
chimeric mice developed papillomas, compared with 50% of control
chimeras, and time of tumour onset was delayed in TNFR /
chimeric mice (Fig. 2a). Although wounds closed more rapidly in
TNFR / chimeras (Supplementary Fig. 2b), in agreement with
observations on TNFR-1 / mice13, the epidermis remained
thickened and hyperproliferative, consistent with the ability of
MEK1 to stimulate keratinocyte proliferation in the absence of
other cell types7 (Fig. 2b). Serum levels of TNF-a were markedly
reduced in tumour-free but not tumour-bearing TNFR /
chimeras (Supplementary Fig. 2c), consistent with MEK1
activation in epidermal tumour cells driving NF-kB activation14.
The tumour-protective effect of TNFR ablation in radio-
sensitive leukocytes correlated with changes in the skin immune
cell infiltrate. CD4þ T cells were markedly reduced in wounds
and papillomas of TNFR / BM chimeras (Fig. 2c,d). When
irradiated InvEE mice were reconstituted with BM from mice
expressing enhanced green fluorescent protein under the control
of the b-actin cytomegalovirus (CMV) promoter and subse-
quently wounded, both the wounds and wound-induced tumours
were heavily infiltrated with F4/80þ macrophages
(Supplementary Fig. 2d). Macrophage (F4/80þ CD11bþ ) and
mast cell numbers were similar in healed wounds of TNFR /
and control chimeras but significantly reduced in tumour stroma
of TNFR / chimeras (Fig. 2e–g).
Epidermal gd T cells infiltrated wounds of both TNFR /
and control chimeras to the same extent. They were never present
within the tumour epithelium, but did accumulate in adjacent
epidermis (Supplementary Fig. 2e), suggesting that the previously
observed reduction in tumours on gd T-cell ablation is an indirect
effect of reduced macrophage recruitment8. TNFR ablation in the
BM did not affect numbers of dendritic cells (CD207þ
CD11cþ ), NK or NKT cells infiltrating wounds or tumours
(Supplementary Fig. 2f–h). B cells (CD19þ ) were not detectable
in unwounded skin or healed wound beds15 and there was no
difference in the stromal B-cell content of TNFR / and control
chimeric tumours (Supplementary Fig. 2i).
We conclude that TNFR ablation in leukocytes protected mice
from developing tumours. It also led to a selective reduction in
CD4þ T cells in wounded skin and a reduction in several
immune cell subsets in tumour stroma.
MyD88 and TLR-5 signalling mediate tumour formation.
MyD88 (Myeloid Differentiation primary response gene 88) is a
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master regulator of innate signalling events as it is the key adaptor
for most TLRs, IL-1R1 and IL-18R16–18. Loss of MyD88 prevents
tumour formation in various tissues19–22. Given that MyD88
controls TNF-a production, we analysed the effect of
reconstituting InvEE mice with MyD88 / radiosensitive
leukocytes. BM chimeras lacking MyD88 in the haematopoietic
compartment exhibited a striking protection against wound-
induced tumour formation (Fig. 3a).
Although InvEE keratinocytes express elevated levels of IL-1a
and administration of the IL-1 receptor antagonist Kineret
decreases tumour formation8,9, no differences in wound-induced
tumour formation were observed between IL-1R1 / BM and
control chimeras (Fig. 3b). We therefore examined the effects of
deleting TLRs. Replacement of the radiosensitive haematopoietic
compartment with TLR-2/-4 / or TLR-9 / cells did not
affect tumour formation (Fig. 3c), in contrast to the role of TLR-4
on haematopoietic and non-haematopoietic cells in chemically
induced skin carcinogenesis23. InvEE mice reconstituted with
TLR-7/-8 / BM exhibited accelerated wound closure
(Supplementary Fig. 3a) but no difference in tumour incidence
was observed (Fig. 3d). TLR-3 and TLR-4 can signal via TIR-
domain-containing adapter-inducing interferon-b (TRIF),
instead of MyD88. However, reconstitution with TRIF / BM
cells had no effect on papilloma formation (Fig. 3e).
Ablation of TLR-5 in radiosensitive leukocytes markedly
reduced the number of tumours that developed on wounding
(Fig. 3d). Wound closure rates were similar in TLR-5 / and
control BM chimeras, suggesting that the dynamics of wound
closure does not affect wound-induced tumour formation
(Fig. 3f).
These findings reveal the significance of an innate MyD88-
TLR-5-sensing axis specifically in BM-derived leukocytes that
drives wound-induced tumour initiation.
Bacterial products mediate tumour initiation in InvEE mice.
As flagellin (Fla), the sole known TLR-5 ligand24, is the main
protein constituent of bacterial flagella, we analysed whether
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Figure 1 | Pro-inflammatory signalling and wound-induced tumour formation in InvEE mice. (a) Correlation between wound diameter and papilloma
incidence at wound site in InvEE mice 30 days post wounding (n420 mice per condition). (b) Incidence of tumours in InvEE mice in 2mm2 (n¼ 28 mice),
5mm2 (n¼ 27 mice) or 8mm2 (n¼ 33 mice) wounds (*0.01oPo0.05; ****Po0.0001; one-way analysis of variance (ANOVA)). (c) Quantification of
CD45þ leukocytes in different sized wounds at time of wound closure (nZ4 mice per condition, at least three microscopic fields were quantified per
mouse; *0.01oPo0.05, **0.01oPo0.001, ***0.0001oPo0.001, ****Po0.0001; two-way ANOVA). (d) Quantitative PCR normalized to glyceraldehyde
3-phosphate dehydrogenase of NF-kB target gene mRNAs in 8-week-old InvEE epidermis relative to transgene negative littermates (log 2-fold upregulation
relative to WT; n¼ 3 mice per condition). Data are means±s.d. of biological and technical triplicates (Po0.0001 for each individual gene product;
unpaired t-test). (e–g) Serum levels of TSLP (e), TNF-a (f) and IL-6 (g) in control, tumour-free and tumour-bearing InvEE mice, assessed by ELISA (n¼4
mice per condition; *0.01oPo0.05, **0.01oPo0.001, ***0.0001oPo0.001; unpaired t-test). Data are means±s.e.m.; pap: papilloma.
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lowering the microbial content of the skin would affect wound-
induced tumour incidence. When mice were treated with the
broad-spectrum antibiotic enrofloxacin (enr), either by
administration in drinking water or topical application, the skin
bacterial load was decreased (Supplementary Fig. 3c, d) and
wound-induced tumour formation was greatly reduced
(Fig. 4a,c). Tumour size in antibiotic-treated mice was greatly
reduced (Fig. 4b), an effect that was previously observed in
intestinal tumours25. No reduction in tumour initiation was
observed when mice were topically treated with methicillin (met;
Fig. 4c), a narrow-spectrum antibiotic that targets Gram-positive
bacteria that are highly abundant on the skin, including the non-
flagellated species Staphylococcus aureus and Staphylococcus
epidermidis.
In mice topically treated with antibiotics, there was no
significant reduction in faecal bacterial load, excluding
involvement of the gut microbiome in wound-induced skin
carcinogenesis (Supplementary Fig. 3e). Broad-spectrum anti-
biotic treatment resulted in a transient increase in wound closure
in WT but not InvEE mice (Supplementary Fig. 3f).
In contrast to the tumour-suppressive effects of TLR-5 ablation
and antibiotic treatment, topical application of flagellin to InvEE
wounds increased tumour incidence in a dose-dependent manner
(Fig. 4d) and delayed wound closure (Fig. 4e and Supplementary
Fig. 3b). Strikingly, intradermal injection of flagellin was sufficient
to induce small tumours in InvEE mice in the absence of
wounding (Fig. 4f). WT mice never developed tumours after
administration of flagellin to wounds or intradermal injection
(data not shown). Flagellin did not induce tumours when injected
into TLR-5 / BM chimeras. When flagellin was administered
to wounds of TLR-5 / BM chimeras, tumour formation was
greatly diminished compared with control chimeras treated with
flagellin (Fig. 4g).
Flagellated bacterial strains are commensals on murine skin26.
When we labelled unwounded InvEE skin with an antibody to the
flagellated Escherichia coli (E. coli) strain K12, we observed strong
immunoreactivity in hair follicles, sebaceous glands and cornified
skin layers (Fig. 4h), in agreement with a previous report26. As
expected, E. coli labelling was markedly reduced in antibiotic-
treated skin. All epidermal layers stained positive for K12 E. coli
in InvEE healed wound beds and papillomas (Fig. 4h).
Taken together, these data demonstrate that exposure to
bacterial flagellin sensed by TLR-5 on radiosensitive leukocytes
promotes tumour formation in InvEE mice.
Role of TLR-5 signalling in carcinogen-induced tumours. To
validate our observations in a second experimental setting,
we induced tumours in WT mice via the classic two-stage
DMBA/TPA (7,12-dimethylbenz(a)anthracene and 12-O-tetra-
decanoylphorbol-13-acetate) chemical carcinogenesis protocol in
which DMBA induces H-Ras mutations and TPA causes chronic
inflammation, promoting tumour development27. Irradiated WT
mice were reconstituted with WT (control) or TLR-5 / BM
and topically treated with DMBA. Mice subsequently received
repeated applications of TPA with or without prior wounding
(Fig. 5a). Wound closure was accelerated in TLR-5 / BM
chimeras treated with TPA (Supplementary Fig. 4a).
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Figure 2 | Role of TNFR signalling in wound-induced tumours. (a) Incidence of papillomas in TNFR-1/-2 / (TNFR //Inv; n¼ 12) and control (Inv/
Inv; n¼ 12) BM chimeras (****Po0.0001; Fisher’s exact test). (b) Epidermal thickness in healed and unwounded skin, defined as the distance from basal to
upper granular layer and measured at ten sites per mouse (wound Inv/Inv: n¼4; wound TNFR //Inv: n¼8; skin Inv/Inv: n¼8; skin TNFR //Inv:
n¼ 10). (c–g) Infiltration of different immune cell populations in wound beds and tumour stroma of post-wounded InvEE and TNFR / chimeric skin
(*0.01oPo0.05; unpaired t-test). (d,f) Histological sections were stained with antibodies to CD3 (red in d) and CD4 (green in d) or CD11b (red in f) and
F4/80 (green in f) and double positive cells were quantified (c,e). Magnified views are represented on the right. (g) Mast cells were quantified following
toluidine blue staining. (c,e,g) nZ3 mice per condition andZ3 fields were quantified per section. Means±s.e.m. are shown. (d,f) Nuclei were stained with
40,6-diamidino-2-phenylindole (blue); dotted lines indicate basement membrane. Scale bars, 300 mm.
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Mice treated with DMBA, but not TPA, and subsequently
wounded, did not develop tumours (data not shown). Control
chimeras that were wounded before TPA treatment developed
tumours after 2 weeks of promotion, which is significantly faster
than mice treated with TPA only (Fig. 5). There was a substantial
delay in the development of DMBA/TPA-induced tumours in
wounded TLR-5 / BM chimeras relative to wounded WT
chimeras (Fig. 5b). The tumour-protective effect of TLR-5 / BM
was also apparent in non-wounded DMBA/TPA-treated mice,
albeit less marked (Fig. 5c). TLR-5 / BM reconstitution did not
reduce the final number of papillomas that formed (Supplementary
Fig. 4b,c) but decreased tumour size considerably (Fig. 5d,e).
We conclude that TLR-5-mediated signalling is involved in
tumour initiation in two different skin cancer models.
Upregulation of HMGB1 in wound-induced tumours. To
investigate the relevance of mouse wound-induced tumour for-
mation to human skin cancer, we analysed SCCs from RDEB
patients. RDEB is a rare skin blistering condition in which
repetitive cycles of wounding and repair predispose the skin to
the development of SCCs6.
HMGB1 is a nuclear danger-associated molecular pattern that
is passively released from necrotic cells and actively secreted
by inflammatory cells28,29. HMGB1 is upregulated in RDEB
patients30,31 and HMGB1 serum levels correlate with RDEB
disease severity30. HMGB1 is also upregulated in a mouse RDEB
model and mediates recruitment of BM-derived cells in injured
tissue31. Furthermore, HMGB1 is induced in epithelial cells
upon exposure to flagellin32. We therefore investigated HMGB1
as a candidate biomarker linking human and mouse wound-
associated skin cancer.
In lesional skin from RDEB patients, HMGB1 was highly
upregulated compared with normal human skin and there was
strong immunoreactivity for HMGB1 in epidermis and dermis
(Fig. 6a; n¼ 6 patients per group). There was an even greater
increase in HMGB1 immunoreactivity in RDEB SCCs (Fig. 6a;
n¼ 6 patients). Although HMGB1 was mainly nuclear in normal
human skin, we observed cytoplasmic HMGB1 in lesional skin
and SCCs from RDEB patients (Fig. 6a), which is indicative of
HMGB1 secretion in these inflammatory conditions29. Consistent
with these findings, HMGB1 was elevated in unwounded InvEE
skin relative to WT (Fig. 6b,c) and further increased on wounding
and in wound-induced papillomas (n¼ 8; Fig. 6b,c). HMGB1
expression was significantly downregulated in skin of unwounded
TLR-5 / /Inv relative to Inv/Inv BM chimeras and the absence
of TLR-5 prevented HMGB1 upregulation on wounding (Fig. 6c).
The reduced immunolabelling in skin correlated with a reduction
in serum HMGB1 levels in wounded mice (Fig. 6d).
We conclude that HMGB1 is upregulated in wound-associated
mouse and human skin tumours and that HMGB1 levels are
regulated by leukocytic TLR-5 signalling.
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Discussion
Host–microbe interactions are crucial for tissue homeostasis and
evidence showing cancer-promoting effects of the commensal
microbiome in various organs is accumulating33–35. Our studies
establish, for the first time, a role for innate sensing of flagellated
bacteria in wound-induced skin cancer. We demonstrate that
TLR-5 ablation in BM-derived leukocytes reduced tumour
incidence in mice and injection of the TLR-5 ligand flagellin
induced papillomas in a TLR-5-dependent manner. Our analysis
of RDEB tumours points to the relevance of our findings to
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human skin cancer. HMGB1, which is induced in epithelial cells
in response to flagellin32, was strongly upregulated in wound-
associated tumours in mice and RDEB patients. Ablation of TLR-
5 in BM cells led to significantly reduced murine HMGB1 serum
levels.
The skin microbiome composition is different across body
surfaces36 and directs local immune responses26,37. The human
microbiome project reference genome database reveals that intact
skin contains flagellated bacterial species (based on the presence
of FliC and FliA genes; http://www.hmpdacc.org/catalog/38).
Consistent with this, a flagellated E. coli strain is present on
InvEE skin26. Although most bacteria are kept at bay by the skin
barrier, in a wound situation the moist and metabolite-rich
environment can promote growth of opportunistic bacteria,
including energetically expensive flagellated species39. Profiling the
microbial configurations in chronic diabetic wounds and leg ulcers
has indicated an increased representation of E. coli, Pseuodomonas
aeruginosa, Shigella and other species comprising flagellated
strains, whereas Staphylococci, a genus that does not comprise
flagellates, are negatively correlated with ulcer duration40,41.
Consistent with the observations in human skin, topical
application of a broad-spectrum antibiotic was tumour protective
in InvEE mice, whereas an antibiotic that targets Staphylocci was
not. These observations lead us to propose that a key, and
previously unrecognized, driver of wound-induced skin cancer is
an increased exposure of leukocytes to flagellated bacteria.
Both of the mouse models in which we demonstrated a role for
leukocytic TLR-5 sensing in wound-induced skin cancer are
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characterized by chronic inflammation. In InvEE mice, the
inflammation results from epidermal expression of constitutively
active MEK1 and in WT mice inflammation is induced by TPA
treatment. TLR-5 ablation in BM does not abolish the
inflammatory infiltrate in InvEE skin or TPA-treated WT skin.
Our studies indicate that in the context of chronic inflammation,
TLR-5 signalling in leukocytes can tip the balance between
normal wound repair and tumour formation. The tumour-
inhibitory effect of ablating TNFR or MyD88 in radiosensitive
leukocytes in InvEE mice was greater than that of TLR-5 ablation
(Figs 2a and 3a,d; 0.01oPo0.05; one-way analysis of variance),
suggesting that additional components of the immune system
that converge on NF-kB may contribute (Fig. 1d).
Our findings raise the possibility that the incidence of SCCs in
non-healing ulcers and skin from RDEB patients could be
reduced by systemic antibiotics treatment and the use of flagellin-
specific targeting strategies in wound-induced malignancies
might present an interesting clinical avenue.
Methods
Mice. InvEE mice9 were maintained on an F1 genetic background (CBAC57Bl/
6) and kept heterogeneous for the MEK1 transgene. Transgene negative littermates
were used as WT controls and in DMBA/TPA experiments. All donor mice in
the BM transplantation experiments were on a C57/Bl6 genetic background.
TLR-5 / and TNFR-1/-2 / mice were purchased from Jackson Laboratories.
TLR-2/-4 / mice were obtained from Simon Clare, IL-1R1 / mice from
Nancy Rothwell, TRIF / mice from Frederic Geissmann, TLR-7/-8 / mice
from Lena Alexapoulou, MyD88 / mice from Caetano Reis e Sousa and
TLR-9 / mice from Kinya Otsu. Animal procedures were subject to local ethical
approval and performed under a UK Government Home Office Licence. Sample
sizes were determined on the basis of prior power calculations. No mice died
as a direct result of wounding or tumour formation. Mice that died as a result
of myeloablation were excluded from analysis.
Wounding and BM reconstitution. Full-thickness wounds were made on the back
skin by using 2, 4, 5, 6 or 8mm2 punch biopsy needles (Stiefel Instruments) under
analgesia and general anaesthesia in 8- to 16-week-old age- and sex-matched InvEE
and control littermates. Statistical power was calculated using the resource equation
and animals were randomly assigned to treatment groups. No animals were
excluded from any experiment. Tumour formation and size were measured by two
independent researchers, who were blinded to group allocations.
In BM transplantation experiments8, 8- to 16-week-old female recipient mice
were treated with acidified water at least 10 days before irradiation. Allogenic BM
transplants were performed 24 h after myeloablative total body irradiation42
(two times 5Gy, separated by 3 h) of InvEE mice. Donor BM was isolated from the
tibia and femur of male mice. BM reconstitution was performed by intravenous
injection of 5 106 BM cells in 200ml of PBS 24 h after irradiation. Chimerism was
confirmed using Y-chromosome in situ hybridization (Cytocell, probe AMPOYR)
on spleens of reconstituted mice8. Mice were wounded 4 to 6 weeks post BM
reconstitution and papilloma formation was monitored for 50 to 60 days post
wounding. Each InvEE BM reconstitution experiment was repeated two to three
times.
Treatment with antibiotics and flagellin. Mice were treated with the broad-
spectrum antibiotic enrofloxacin by oral administration (5ml Baytril per liter
drinking water) starting 8 days before wounding and continuing until the end of
the experiment. For topical applications, shaved back skin of mice was treated daily
with 200 ml of vehicle (acetone) or antibiotics in acetone starting 8 days before
wounding. Antibiotics used were 0.25% enrofloxacin or 0.2mgml 1 methicillin.
Skin swabs were taken on day 10 post wounding and plated on lysogeny broth (LB)
and blood agar plates to verify bacterial depletion. 16S rRNA quantification was
performed on skin biopsies taken at the time of wounding.
1 or 4 mg flagellin (high-purity flagellin, EnzoLifeSciences) was injected once
intradermally in back skin in 100 ml PBS; control mice were injected with 100 ml
PBS. Flagellin was applied once topically to 8mm2 full-thickness skin wounds at
time of wounding.
Quantitative PCR. Epidermis was separated from the underlying dermis by
scraping skin after incubation at 60 C for 7 s in RNase-free water. Isolated epi-
dermis was homogenized in lysis buffer using ceramic beads. RNA extraction was
performed according to the manufacturer’s instructions using a QIAGEN RNeasy
Kit (Qiagen). Complementary DNA was generated using reverse transcriptase III
(Invitrogen). Quantitative real-time PCR reactions were set up using gene-specific
primer sets (see Supplementary Table 1) and reactions were performed on a
7900HT real-time PCR machine (Applied Biosystems) on biological triplicates.
Microbiota quantification. Bacterial load was quantified in skin biopsy samples
(8mm2) and in faeces collected from mice 8 days after antibiotic treatment.
Samples were digested with Ready-Lyse Lysozyme Solution (Epidentre Bio-
technologies) in lysis buffer (20mM Tris, pH 8.0, 2mM EDTA, 1.2% Triton X-100,
DNA-free water). Samples were homogenized using 5mm Stainless Steel Beads
(Qiagen) in a Precellys homogenizer twice at 6,000 r.p.m. for 50 s. DNA was
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diamidino-2-phenylindole (blue). Dotted line denotes basement membrane. Arrows denote wound edge. Scale bars, 200mm. (a) Normal human skin,
lesional RDEB skin and RDEB SCCs. (b) WT skin, InvEE healed wound bed (26 days post wounding) and wound-induced papilloma. (c) Unwounded and
wounded InvEE/InvEE and InvEE/TLR5 / BM chimeras. (d) Serum levels of HMGB1 in non-tumour-bearing InvEE/InvEE and InvEE/TLR5 / BM
chimeras at day 26 post wounding, assessed by ELISA (n¼ 9 mice per condition; *0.01oPo0.05; Mann–Whitney U-test). Data are means±s.e.m.
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extracted using a Purelink Genomic DNA kit (Invitrogen). For 16S rRNA quan-
tification, the following primers were used: 50-AGAGTTTGATCCTGGCTCAG-30
and 50-CTGCTGCCTCCCGTAGGAGT-30 . Data for skin bacterial load were
normalized against the relative mouse genomic DNA amplicon quantification.
Primers used were 50-TTAGCAGTTTGGCACAGCTAGG-30 and 50-CTAGGTT
GGCAAGGAATTGTGG-30.
ELISA. Blood was collected by cardiac puncture and left to clot for 2 h. Serum was
collected after centrifugation for 20min at 4 C. TNF-a, IL-6 and TSLP levels were
quantified using Quantikine ELISA kits (R&D systems). HMGB1 serum levels were
measured by ELISA (Shino-test Corporation).
DMBA/TPA two-stage carcinogenesis. Chemical carcinogenesis experiments
were performed as previously described27. In brief, back skin of mice was shaved
and treated once with 100 nmol (25mg) DMBA in 200ml acetone 5 weeks after BM
reconstitution. Seven days later, mice were either wounded with an 8mm2 full-
thickness skin biopsy punch or treated with 6 nmol (3.7 mg) TPA. After 2 days, all
mice were treated three times weekly with TPA for 15 weeks. Tumour incidence
and burden were assessed once a week by two independent researchers who were
blinded to the group allocations.
Immunofluorescence staining. Frozen sections were fixed in acetone/methanol
(1:1) or 4% paraformaldehyde/PBS pH 7.4 and blocked with 2% BSA, 0.02% fish
skin gelatin and 10% goat serum for 1 h in PBS at room temperature. Paraffin
sections were subjected to heat-mediated antigen retrieval (citrate buffer, pH6).
When fluorochrome-conjugated primary antibodies were used, sections were
incubated overnight at 4 C in antibody solution containing 40 ,6-diamidino-2-
phenylindole, washed in PBS and then mounted using the DAKO mounting
reagent (DAKO). In the case of the unconjugated primary antibodies (HMGB1,
Abcam, ab79823; anti-Escherichia coli antibody, DAKO, B0357), incubation was
overnight at 4 C followed by 2 h incubation at room temperature in secondary
antibody (AlexaFluor 555 goat-anti-rabbit) containing 40 ,6-diamidino-2-pheny-
lindole. Alexafluor 647-, 660- or 488-conjugated antibodies to CD3 (BioLegend,
clone 17.A2), CD4 (eBioscience, clone RM4-5), F4/80 (eBioscience, clone BM8),
CD19 (eBioscience, eFluor 660), CD11b (eBioscience, clone M1/70), CD11c
(Cambridge Bioscience), gd TCR (BD Pharmingen, clone GL3), NK1.1 (BioLegend,
clone PK136) and CD207 (eBioscience, eFluor 660) were used.
Immunohistochemistry. Dewaxed paraffin sections were subjected to heat-
mediated antigen retrieval (citrate buffer, pH6). Mast cells were quantified by
counting toluidine blue-stained cells on paraffin skin sections. CD45 (BD Phar-
mingen, clone 30-F11) antibody was used on paraffin sections at 1:100 dilution.
Quantification of immune cell infiltration was performed within the wound and
adjacent to the wound (maximum distance from wound/pap: 4mm) or in tumour
stroma.
Human samples. All human samples were collected after informed, written
consent and in accordance with Helsinki guidelines, in compliance with the UK
Human Tissue Act. The study protocol was approved by the Universities of
Monterrey and New South Wales.
Statistics. Statistical analyses were performed using GraphPad Prism v6. Specific
tests included Fisher’s exact tests, one or two-way analysis of variance, unpaired t-
tests and Mann–Whitney tests. *0.01oPo0.05, **0.01oPo0.001,
***0.0001oPo0.001, ****Po0.0001.
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